Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RECQL | P46063 | 1/20 | 0.53 |
| ▸ | GAA | P10253 | 4/20 | 0.50 |
| ▸ | EGFR | P00533 | 1/20 | 0.49 |
| ▸ | CNR1 | P21554 | 1/20 | 0.49 |
| ▸ | CNR2 | P34972 | 1/20 | 0.49 |
| ▸ | NOS2 | P35228 | 2/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.48 |
| ▸ | LMNA | P02545 | 2/20 | 0.48 |
| ▸ | NPC1 | O15118 | 2/20 | 0.48 |
| ▸ | POLB | P06746 | 1/20 | 0.48 |
| ▸ | AGTR1 | P30556 | 1/20 | 0.48 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.47 |
| ▸ | NLRP1 | Q9C000 | 1/20 | 0.47 |
| ▸ | MAPT | P10636 | 5/20 | 0.47 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.47 |
| ▸ | HTT | P42858 | 1/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.45 |
| ▸ | HPGD | P15428 | 1/20 | 0.45 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.45 |
| ▸ | TSHR | P16473 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6351799 | 0.85 | RECQL (0.64) | RECQLGAANOS2ALDH1A1NPC1 | |
| SCHEMBL9063310 | 0.84 | GAA (0.59) | GAAEGFRCNR1CNR2ALDH1A1 | |
| SCHEMBL48194 | 0.83 | CNR2 (0.57) | GAAEGFRCNR1CNR2ALDH1A1 | |
| SCHEMBL10396907 | 0.83 | MAPT (0.67) | RECQLGAANOS2ALDH1A1LMNA | |
| SCHEMBL11311902 | 0.82 | CNR2 (0.53) | GAAEGFRCNR1CNR2ALDH1A1 | |
| SCHEMBL12653273 | 0.82 | RECQL (0.60) | RECQLGAANOS2ALDH1A1NPC1 | |
| SCHEMBL4844927 | 0.82 | MAPT (0.70) | RECQLGAAALDH1A1LMNANPC1 | |
| SCHEMBL6332774 | 0.81 | RECQL (0.58) | RECQLALDH1A1LMNANPC1POLB | |
| SCHEMBL10370243 | 0.81 | MAPT (0.65) | GAAALDH1A1NPC1POLBMAPK1 | |
| SCHEMBL9712508 | 0.81 | GAA (0.49) | GAAEGFRCNR1CNR2ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7939545-B2 | additionally comprising at least one other antiviral agent | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2011-05-10 | — | — | US | disclosed |
| US-7939545-B2 | additionally comprising at least one other antiviral agent | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2011-05-10 | — | — | US | disclosed |
| EP-2019825-B9 | INHIBITORS OF HUMAN IMMUNODEFICIENCY VIRUS REPLICATION | BOEHRINGER INGELHEIM INT (DE) | 2011-01-26 | — | — | EP | disclosed |
| EP-2019825-B1 | INHIBITORS OF HUMAN IMMUNODEFICIENCY VIRUS REPLICATION | BOEHRINGER INGELHEIM INT (DE) | 2010-09-01 | — | — | EP | disclosed |
| US-20080221159-A1 | Inhibitors of human immunodeficiency virus replication | GILEAD SCIENCES, INC. | 2008-09-11 | — | — | US | disclosed |
| US-20080221159-A1 | Inhibitors of human immunodeficiency virus replication | GILEAD SCIENCES, INC. | 2008-09-11 | — | — | US | disclosed |
| US-7326788-B2 | Selective, potent small molecule protein tyrosine kinase inhibitors; such as 6-chloro-3-(3-methyl-isoxazol-5-yl)-4-(pyridin-4-yl)-1H-quinolin-2-one | JANSSEN PHARMACEUTICA N.V. (BE) | 2008-02-05 | — | — | US | disclosed |
| US-7326788-B2 | Selective, potent small molecule protein tyrosine kinase inhibitors; such as 6-chloro-3-(3-methyl-isoxazol-5-yl)-4-(pyridin-4-yl)-1H-quinolin-2-one | JANSSEN PHARMACEUTICA N.V. (BE) | 2008-02-05 | — | — | US | disclosed |
| US-7326788-B2 | Selective, potent small molecule protein tyrosine kinase inhibitors; such as 6-chloro-3-(3-methyl-isoxazol-5-yl)-4-(pyridin-4-yl)-1H-quinolin-2-one | JANSSEN PHARMACEUTICA N.V. (BE) | 2008-02-05 | — | — | US | disclosed |
| WO-2007131350-A1 | INHIBITORS OF HUMAN IMMUNODEFICIENCY VIRUS REPLICATION | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2007-11-22 | — | — | WO | disclosed |
| EP-1660087-A2 | QUINOLINONE DERIVATIVES AS INHIBITORS OF C-FMS KINASE | JANSSEN PHARMACEUTICA N.V. (BE) | 2006-05-31 | — | — | EP | disclosed |
| US-20050049274-A1 | Quinolinone derivatives as inhibitors of c-fms kinase | JANSSEN PHARMACEUTICA, N.V. (BE) | 2005-03-03 | — | — | US | disclosed |
| WO-2005009967-A2 | QUINOLINONE DERIVATIVES AS INHIBITORS OF C-FMS KINASE | JANSSEN PHARMACEUTICA, N.V. (BE) | 2005-02-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080221159-A1 | Inhibitors of human immunodeficiency virus replication | RTF2, RTF1, POLR1E | RECQL 30/4885GAA 1927/4885EGFR 2731/4885 |
| US-20050049274-A1 | Quinolinone derivatives as inhibitors of c-fms kinase | FLT3, ABL1, FES | RECQL 838/4885GAA 4452/4885EGFR 271/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.